glp1
Bydureon BCise (exenatide extended-release) tracker
Educational reference for Bydureon BCise (exenatide extended-release). Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
—
Tmax
—
Category
glp1
Also known as: bydureon, exenatide-er, exenatide extended release
Bydureon BCise is the once-weekly extended-release exenatide product.
Mechanism
An extended-release microsphere formulation of exenatide, a GLP-1 receptor agonist. Drug release from the microspheres, not elimination, controls its time course.
Research summary
FDA-approved once-weekly product for type 2 diabetes. It is a separate formulation from immediate-release exenatide (Byetta).
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Bydureon BCise prescribing information · FDA prescribing informationRelease-limited extended-release formulation; steady state is reached after several weeks of weekly use and there is no single elimination half-life, so none is shown.
Το TrackPep είναι εφαρμογή παρακολούθησης. Καταγράφει όσα καταχωρίζεις και ποτέ δεν προτείνει ούτε υπολογίζει ποσότητες.